Generic Name and Formulations:
Canakinumab 180mg/vial; pwd for SC inj after reconstitution; preservative-free.

Company:
Novartis Pharmaceuticals Corp
Indications for ILARIS:
Systemic juvenile idiopathic arthritis (SJIA) in patients ≥2yrs of age.

Adult:
Not recommended.

Children:
Give as SC inj every 4 weeks. <2yrs: not recommended. ≥2yrs: (≥7.5kg): 4mg/kg; max 300mg.

Warnings/Precautions:
Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Risk of macrophage activation syndrome. Pregnancy (Cat.C). Nursing mothers.

Interactions:
Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Pharmacological Class:
Interleukin-1beta blocker.

Adverse Reactions:
Nasopharyngitis, diarrhea, influenza, headache, nausea, inj site reactions; increased risk of infections, malignancies.

How Supplied:
Vial—1
Indications for ILARIS:
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children ≥4yrs of age including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS).

Adults and Children:
Give as SC inj every 8 weeks as a single dose. <4yrs: not recommended. ≥4yrs: (15–40kg): 2mg/kg; children with inadequate response: may increase to 3mg/kg; (>40kg): 150mg.

Warnings/Precautions:
Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Risk of macrophage activation syndrome. Pregnancy (Cat.C). Nursing mothers.

Interactions:
Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Pharmacological Class:
Interleukin-1beta blocker.

Adverse Reactions:
Nasopharyngitis, diarrhea, influenza, headache, nausea, inj site reactions; increased risk of infections, malignancies.

How Supplied:
Vial—1